The News Review:

- The therapeutic misconception: informed consent in psychiatric…
- Clinical Trials Directive still hampering academic medical research
- Award Winner: Carolina Eye Physician Receives Duke Honor
- Genzyme begins phase 3 trials of Campath for MS

The therapeutic misconception: informed consent in psychiatric…
Nature.com – Nature.com (subscription) – Sep 27, 2007
Misunderstanding in clinical research: distinguishing therapeutic misconception therapeutic misestimation and therapeutic optimism. 25 1–16 (2003).

Clinical Trials Directive still hampering academic medical research
eurekalert.org – Sep 27, 2007
The work is a first attempt to create a comprehensive picture at EU level of the outcome of the Directive three years after its coming into force” he said. “Because the follow-up time is quite short it is still difficult to report final outcome figures particularly given that some countries such as France and The Netherlands did not fully implement the Directive until 2006. But the data for non-commercial clinical research in general confirms that academic research which represented around a quarter of all clinical trials of drugs before implementation lost ground and represents now less than one fifth of newly started trials. ” Although the size of the effect is below initially reported estimates from different sponsor organisations the current trend remains negative. However latest figures reported by national authorities indicate that the pre-implementation level for new clinical trial authorisations may be achieved again in the coming 12 months at least for commercial trials. Because the Directive changed the standards for trial reporting many countries had to revise their way of compiling data and as a result the pre- and post-implementation statistics are not fully comparable. During the pre-implementation period most authorities did not report many details.

Award Winner: Carolina Eye Physician Receives Duke Honor
Southern Pines Pilot – Sep 27, 2007
“This award means a great deal since it was not exclusively given to me by my mentors and faculty but it also comes from the residents that I worked with while we handled eye traumas and surgeries at Duke during some long nights. His fellowship at the Duke University Eye Center focused upon diseases and surgery of the retina and vitreous specifically macular degeneration retinal detachments and diabetic eye disease. Shuler is recognized for his basic science and clinical research and has published widely including recent papers in Archives of phthalmology American Journal of phthalmology and phthal-mology. At Carolina Eyeadvertisement.

Genzyme begins phase 3 trials of Campath for MS
Boston Globe – Sep 27, 2007
(Bloomberg)Parexel completes $50. 9m buy of Taiwan company Parexel International Corp. a Waltham biopharmaceutical services company said it completed the acquisition of Taiwan-based Apex International Clinical Research Co. Under terms of the tender offer Parexel paid about $2. 51 for each Apex share of common stock.